These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34827546)

  • 21. Aducanumab Therapy to Treat Alzheimer's Disease: A Narrative Review.
    Beshir SA; Aadithsoorya AM; Parveen A; Goh SSL; Hussain N; Menon VB
    Int J Alzheimers Dis; 2022; 2022():9343514. PubMed ID: 35308835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Review of Scientific Ethics Issues Associated with the Recently Approved Drugs for Alzheimer's Disease.
    Yeo-Teh NSL; Tang BL
    Sci Eng Ethics; 2023 Jan; 29(1):2. PubMed ID: 36625928
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019.
    Knopman DS; Jones DT; Greicius MD
    Alzheimers Dement; 2021 Apr; 17(4):696-701. PubMed ID: 33135381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alzheimer's and Aducanumab: Unjust Profits and False Hopes.
    Fleck LM
    Hastings Cent Rep; 2021 Jul; 51(4):9-11. PubMed ID: 34156732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Under-Represented Populations Left Out of Alzheimer's Disease Treatment with Aducanumab: Commentary on Ethics.
    Padala SP; Yarns BC
    J Alzheimers Dis Rep; 2022; 6(1):345-348. PubMed ID: 35891635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aducanumab, a Novel Anti-Amyloid Monoclonal Antibody, for the Treatment of Alzheimer's Disease: A Comprehensive Review.
    Haddad HW; Malone GW; Comardelle NJ; Degueure AE; Kaye AM; Kaye AD
    Health Psychol Res; 2022; 10(1):31925. PubMed ID: 35928986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. "Aducanumab" making a comeback in Alzheimer's disease: An old wine in a new bottle.
    Behl T; Kaur I; Sehgal A; Singh S; Sharma N; Makeen HA; Albratty M; Alhazmi HA; Felemban SG; Alsubayiel AM; Bhatia S; Bungau S
    Biomed Pharmacother; 2022 Apr; 148():112746. PubMed ID: 35231697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impacts of FDA approval and Medicare restriction on antiamyloid therapies for Alzheimer's disease: patient outcomes, healthcare costs, and drug development.
    Brockmann R; Nixon J; Love BL; Yunusa I
    Lancet Reg Health Am; 2023 Apr; 20():100467. PubMed ID: 36908502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aducanumab: The first targeted Alzheimer's therapy.
    Yang P; Sun F
    Drug Discov Ther; 2021; 15(3):166-168. PubMed ID: 34234067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aducanumab for Alzheimer's disease: A regulatory perspective.
    Nisticò R; Borg JJ
    Pharmacol Res; 2021 Sep; 171():105754. PubMed ID: 34217830
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Aducanumab and Alzheimer's disease: a critical reflection.].
    Vanacore N; Blasimme A; Canevelli M
    Recenti Prog Med; 2021; 112(7):495-498. PubMed ID: 34263875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Consensus Statement Regarding the Application of Biogen to Health Canada for Approval of Aducanumab.
    Chertkow H; Rockwood K; Hogan DB; Phillips N; Montero-Odasso M; Amanullah S; Black S; Bocti C; Borrie M; Feldman H; Freedman M; Hsiung R; Kirk A; Masellis M; Nygaard H; Rajji T; Verret L
    Can Geriatr J; 2021 Dec; 24(4):373-378. PubMed ID: 34912492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aducanumab: First Approval.
    Dhillon S
    Drugs; 2021 Aug; 81(12):1437-1443. PubMed ID: 34324167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aducanumab for the treatment of Alzheimer's disease.
    Tagliapietra M
    Drugs Today (Barc); 2022 Oct; 58(10):465-477. PubMed ID: 36305541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Navigating Disease-Modifying Treatments for Alzheimer's Disease: Focusing on Medications in Phase 3 Clinical Trials.
    Brandt NJ; Wheeler C; Courtin SO
    J Gerontol Nurs; 2023 Jan; 49(1):6-10. PubMed ID: 36594914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials.
    Wu W; Ji Y; Wang Z; Wu X; Li J; Gu F; Chen Z; Wang Z
    Eur J Med Res; 2023 Nov; 28(1):544. PubMed ID: 38017568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. From monomer to fibril: Abeta-amyloid binding to Aducanumab antibody studied by molecular dynamics simulation.
    Frost CV; Zacharias M
    Proteins; 2020 Dec; 88(12):1592-1606. PubMed ID: 32666627
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Making the Case for the Accelerated Withdrawal of Aducanumab.
    Whitehouse PJ; Saini V
    J Alzheimers Dis; 2022; 87(3):999-1001. PubMed ID: 35491796
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab.
    Mallinckrodt C; Tian Y; Aisen PS; Barkhof F; Cohen S; Dent G; Hansson O; Harrison K; Iwatsubo T; Mummery CJ; Muralidharan KK; Nestorov I; Nisenbaum L; Rajagovindan R; von Hehn C; van Dyck CH; Vellas B; Wu S; Zhu Y; Sandrock A; Chen T; Budd Haeberlein S
    J Prev Alzheimers Dis; 2023; 10(2):171-177. PubMed ID: 36946443
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.